Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori

Author：

E-ISSN： 1791-244X|36|2|363-368

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.36, Iss.2, 2015-01, pp. : 363-368

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High Helicobacter pylori cure rate with sitafloxacin‐based triple therapy

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 477-483

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ten‐day triple therapy versus sequential therapy versus concomitant therapy as first‐line treatment for Helicobacter pylori infection

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1134-1139

John Wiley & Sons Inc

Access to resources Recommend Favorite

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

By Li Yuqin

Wiener klinische Wochenschrift, Vol. 122, Iss. 13-14, 2010-07 ,pp. : 413-422

Springer Publishing Company

Access to resources Recommend Favorite

Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 581-589

John Wiley & Sons Inc

Access to resources Recommend Favorite

Helicobacter pylori treatment in children: Defining a dose for rabeprazole as a part of a triple therapy regimen

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 5, 2015-05 ,pp. : 592-600

John Wiley & Sons Inc

Access to resources Recommend Favorite